178 related articles for article (PubMed ID: 36931016)
21. Prognostic Model of Colorectal Cancer Constructed by Eight Immune-Related Genes.
Wen S; He L; Zhong Z; Mi H; Liu F
Front Mol Biosci; 2020; 7():604252. PubMed ID: 33330631
[TBL] [Abstract][Full Text] [Related]
22. The possible role of SRMS in colorectal cancer by bioinformatics analysis.
Zhang J; Liu W; Feng S; Zhong B
World J Surg Oncol; 2021 Nov; 19(1):326. PubMed ID: 34781983
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer.
Busenhart P; Montalban-Arques A; Katkeviciute E; Morsy Y; Van Passen C; Hering L; Atrott K; Lang S; Garzon JFG; Naschberger E; Hartmann A; Rogler G; Stürzl M; Spalinger MR; Scharl M
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131862
[TBL] [Abstract][Full Text] [Related]
24. Reclassifying TNM stage I/II colorectal cancer into two subgroups with different overall survival, tumor microenvironment, and response to immune checkpoint blockade treatment.
Liu X; Qin J; Nie J; Sun H; Pan Y; Wang S
Front Genet; 2022; 13():948920. PubMed ID: 36212126
[No Abstract] [Full Text] [Related]
25. Comprehensive analysis of transient receptor potential channels-related signature for prognosis, tumor immune microenvironment, and treatment response of colorectal cancer.
Wang L; Chen X; Zhang H; Hong L; Wang J; Shao L; Chen G; Wu J
Front Immunol; 2022; 13():1014834. PubMed ID: 36389750
[TBL] [Abstract][Full Text] [Related]
26. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
[TBL] [Abstract][Full Text] [Related]
27. Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer.
Al-Badran SS; Grant L; Campo MV; Inthagard J; Pennel K; Quinn J; Konanahalli P; Hayman L; Horgan PG; McMillan DC; Roxburgh CS; Roseweir A; Park JH; Edwards J
J Pathol Clin Res; 2021 Mar; 7(2):121-134. PubMed ID: 33338327
[TBL] [Abstract][Full Text] [Related]
28. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
Lin A; Zhang J; Luo P
Front Immunol; 2020; 11():2039. PubMed ID: 32903444
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
[TBL] [Abstract][Full Text] [Related]
30. Potential Therapeutic Targets of B7 Family in Colorectal Cancer.
Wang C; Feng H; Cheng X; Liu K; Cai D; Zhao R
Front Immunol; 2020; 11():681. PubMed ID: 32477326
[TBL] [Abstract][Full Text] [Related]
31. SLAMF8 Promotes Atherosclerosis by Activating the TLR4 Signaling Pathway in Rheumatoid Arthritis.
Lin Z; Sun G; Ou Z; Wei Y; Wang Y
Altern Ther Health Med; 2024 Jun; ():. PubMed ID: 38836739
[TBL] [Abstract][Full Text] [Related]
32. SLC2A1 is a Diagnostic Biomarker Involved in Immune Infiltration of Colorectal Cancer and Associated With m6A Modification and ceRNA.
Liu XS; Yang JW; Zeng J; Chen XQ; Gao Y; Kui XY; Liu XY; Zhang Y; Zhang YH; Pei ZJ
Front Cell Dev Biol; 2022; 10():853596. PubMed ID: 35399515
[No Abstract] [Full Text] [Related]
33. Interferon regulatory factor family influences tumor immunity and prognosis of patients with colorectal cancer.
Chen YJ; Luo SN; Dong L; Liu TT; Shen XZ; Zhang NP; Liang L
J Transl Med; 2021 Sep; 19(1):379. PubMed ID: 34488791
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Impact of PD-1 and Tim-3 Expression in Tumor Tissue in Stage I-III Colorectal Cancer.
Kuai W; Xu X; Yan J; Zhao W; Li Y; Wang B; Yuan N; Li Z; Jia Y
Biomed Res Int; 2020; 2020():5294043. PubMed ID: 32509862
[TBL] [Abstract][Full Text] [Related]
35. Integrated analysis and validation reveal ACAP1 as a novel prognostic biomarker associated with tumor immunity in lung adenocarcinoma.
Wang N; Zhu L; Xu X; Yu C; Huang X
Comput Struct Biotechnol J; 2022; 20():4390-4401. PubMed ID: 36051873
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
37. Identification of the Crucial Role of CCL22 in
Wang H; Luo K; Guan Z; Li Z; Xiang J; Ou S; Tao Y; Ran S; Ye J; Ma T; Qiao T; Zhang Z; Jin Y; Song Y; Huang R
Front Genet; 2022; 13():811900. PubMed ID: 35295948
[TBL] [Abstract][Full Text] [Related]
38. Pan-cancer analysis reveals interleukin-17 family members as biomarkers in the prediction for immune checkpoint inhibitor curative effect.
Han X; Ye J; Huang R; Li Y; Liu J; Meng T; Song D
Front Immunol; 2022; 13():900273. PubMed ID: 36159856
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of NOP14 is associated with improved prognosis due to immune regulation in colorectal cancer.
Lu C; Liao W; Huang Y; Huang Y; Luo Y
BMC Gastroenterol; 2022 Apr; 22(1):207. PubMed ID: 35473611
[TBL] [Abstract][Full Text] [Related]
40. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
Front Immunol; 2021; 12():665002. PubMed ID: 34367132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
